EP is a community where members connect through shared life experiences-- like MS--and so much more. You are not defined by any one thing, so be your true self and find others just like you at
Experience Project.
The Therapeutic Goods Administration in Australia has awarded Aimspro “Orphan Drug Status” in the treatment of Krabbe’s Leukodystrophy, a serious inherited disease of the nervous system. This condition is characterised by the failure of the myelin sheaths surrounding nerve fibres to develop normally.
Formal controlled, double blinded trials will now take place in Australia to assess the medication’s efficacy in treating this rare, disabling condition.
You cannot post new topics in this forum You cannot reply to topics in this forum You cannot edit your posts in this forum You cannot delete your posts in this forum You cannot vote in polls in this forum
We encourage you to also visit our Multiple Sclerosis story and support community on Experience Project.
Experience Project is a vast and powerful community where people connect anonymously through life experiences. It's made by the same people who built This is MS,
on the premise that no one life experience-- like having MS-- defines a person. It now covers over 2 million life stories. Find and share yours!
Forum FAQ
Search
Usergroups
Profile
Log in to check your private messages
Log in
